Finn
SHC Healthcare Services · Sterilization · Medical devices · Legal risk · Thesis updated November 15, 2026

Strong core operations battling a legal shadow and market softness

01 Running thesis

Good business, hard overhang

Sotera sits in a needed part of healthcare. Many medical devices and drug products must be sterilized before use. Customers do not pick these services lightly, because failure can stop product shipments or create safety issues.

The bull case starts with the link between Sterigenics and Nordion. Sterigenics runs sterilization services. Nordion supplies Cobalt-60, the isotope used in gamma sterilization. That gives Sotera more control over a key input than many rivals have, and Q3 2026 showed strong pricing power in the main sterilization business. The company also reached its long-term leverage target of 2.9x, prompting a credit upgrade from Moody's and preparing for high free cash flow in 2027 as heavy capital spending rolls off.

The bear case centers on two factors. Ethylene oxide, or EO, is a gas used to sterilize products that cannot handle heat or radiation. It has also created a long legal fight over emissions. The biggest open questions are the remaining Georgia claims and a California trial slated for early 2027. Second, emerging European medical device softness is expected to flatten sequential Q4 growth for Sterigenics, creating concern that demand sluggishness could bleed into the United States.

The end of 2026 is showing whether new leadership can keep Nelson Labs growing, push X-ray and other alternatives forward, and decide how to allocate significant expected cash flow in 2027.

Nov 2026→Q3 2026 results showed the company achieved its target leverage of 2.9x with strong pricing power, but management noted emerging softness in European medical device markets.
Aug 2026▲Q2 2026 results exceeded expectations with revenue of $321 million. Former private equity sponsors completed their final secondary offering, and the New Mexico EO litigation was settled.
May 2026→Q1 2026 revenue beat expectations and operating cash flow stayed positive despite the $34.0 million EO settlement payment. The same update also showed Nelson Labs weakening and confirmed Alton Shader as the incoming CEO.
Feb 2026▼The 2025 10-K gave a clearer view of the EO risk, including about 755 Georgia claims still pending. It also confirmed investment in X-ray and NO2 as possible long-term EO alternatives.
Nov 2025▲Sterigenics and Nordion posted strong Q3 2025 revenue growth. Nelson Labs revenue still fell, but margin expansion made the operating story look better at that point.
Aug 2025→The core business improved in Q2 2025, with Sterigenics revenue up 10.5 percent and Nelson Labs margins improving. A new $34.0 million Illinois EO settlement kept the legal overhang in place.
02 Business model

Paid to make products usable

Sotera makes money by doing work that healthcare companies often cannot skip. A medical device maker may need sterilization, lab testing, and expert advice before a product reaches hospitals. Sotera charges for those services across a product's life, from development through shipping.

Sterigenics is the largest piece. It uses gamma irradiation, EO processing, and E-beam irradiation to sterilize medical devices, drugs, and some food safety products. This business can be sticky because customers must validate their process, which means prove that a specific plant and method works for their product.

Nordion is the supply backbone for gamma sterilization. It sells Cobalt-60 and gamma systems, and it helps support Sterigenics' position. Nelson Labs is different. It provides microbiology, chemistry testing, and advisory work.

The model breaks if legal costs or new rules eat the cash that the core business produces, or if European end-market softness spreads. Sotera generated positive operating cash flow recently and improved its balance sheet, but that does not remove the risk of more settlements or higher environmental spending.

03 Product portfolio

Sterilization, supply, and testing

Cash cow

Sterigenics gamma sterilization

Gamma sterilization uses radiation to sterilize large batches of products. It is helped by Sotera's Nordion supply link.

Steady

Sterigenics EO processing

EO can sterilize products that may not work well with heat or some forms of radiation. It is useful, but it is also the center of Sotera's largest legal and regulatory risk.

Option

E-beam and X-ray sterilization

E-beam is already part of the service mix, while a new X-ray facility began generating revenue in late 2026. These methods could help reduce long-term dependence on EO.

Growth engine

Nordion Cobalt-60 supply

Nordion supplies Cobalt-60, a key input for gamma sterilization, and sells gamma irradiation systems. Revenue fluctuates based on Co-60 harvest timing.

Steady

Nelson Labs testing and advisory

Nelson Labs tests products and gives technical advice to medical device and pharma customers. It returned to growth in 2026 with strong expert advisory services demand.

Option

NO2-based sterilization investment

Sotera is investing in nitrogen dioxide based sterilization technology. This is an option on future demand for alternatives to EO.

04 Business segments

Q3 mix still favors sterilization

Sterigenics64%modest
Nordion17%flat
Nelson Labs19%modest

Segment shares use Q3 2026 net revenues: Sterigenics $209 million, Nordion $55 million, and Nelson Labs $61 million. The mix can move quarter to quarter because Nordion revenue depends partly on Co-60 harvest timing.

05 Risk factors

What could go wrong

EO litigation keeps draining cash

High impact · High odds

EO lawsuits are the main risk to the stock story. Sotera settled New Mexico claims for an immaterial amount, but the Georgia appellate process remains unresolved and a California trial is expected in early 2027.

We watchWatch new EO settlements, the California trial dates, and changes in the count of Georgia claims.

European medical device softness

Medium impact · Medium odds

Management noted broad-based softness in Europe during late Q3 2026. If this spreads to the US or persists, it will dampen volume growth for the core Sterigenics segment.

We watchWatch Q4 2026 Sterigenics sequential growth and any commentary on US customer demand.

EPA rules force more spending

High impact · Medium odds

EO is useful but closely watched by regulators. The company already expected environmental facility enhancements to be a large capital use. If the EPA or local regulators tighten rules again, Sotera may need to spend more than planned.

We watchWatch EPA EO rule updates and Sotera's capital spending guidance for environmental projects.

Alternative sterilization adoption takes time

Medium impact · Medium odds

X-ray, E-beam, and NO2 could reduce some long-term EO risk. The new X-ray facility is generating revenue, but customers must test and approve new sterilization methods for each product.

We watchWatch the commercial adoption, customer wins, and revenue contribution from the new X-ray facility in 2027.

Nordion timing impacts results

Medium impact · Medium odds

Nordion revenue dropped 11.5 percent in Q3 2026 due to unfavorable Co-60 harvest schedule timing. This timing can mask the true base demand for the segment in any given quarter.

We watchWatch Nordion volume and mix after harvest timing normalizes.
06 Quick answers

In one breath

What does Sotera Health do?

Sotera helps healthcare companies sterilize products, source Cobalt-60 for gamma sterilization, and test medical products in labs. Its main customers are medical device, pharmaceutical, and related healthcare companies.

Why is ethylene oxide important to Sotera?

Ethylene oxide, or EO, is a sterilization gas used for products that may not work with other methods. It is also the source of major lawsuits and regulatory risk for Sotera.

Why did Sotera change CEOs in 2026?

The company named Alton Shader as CEO effective May 26, 2026, with Michael Petras moving to Executive Chairman. The key investor question is whether the new CEO changes capital allocation and speeds the shift to alternative sterilization.

Is Sotera mostly a lab testing company?

No. Nelson Labs is meaningful, but Sterigenics is the largest segment by revenue. The main investment debate is still about sterilization strength versus EO legal risk.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Sotera Health Q3 2026 Earnings Call Transcript
  2. Sotera Health Q3 2026 Form 10-Q
  3. Sotera Health Q2 2026 Form 10-Q
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Sotera Health Company in Finn's Diagnostics & Research industry ranking.

Get started with Finn today